Journal of Clinical Epidemiology
Volume 49, Issue 2 , Pages 203-209 , February 1996

IgE predicts future nonfatal myocardial infarction in men

  • Robert D. Langer

      Affiliations

    • Corresponding Author InformationAll correspondence should be addressed to: Robert D. Langer, MD, MPH, Division of Epidemiology, UCSD School of Medicine MC 0607, La Jolla, CA 92093-0607, U.S.A..
    • Department of Community and Family Medicine, 0607 Division of Epidemiology, School of Medicine, University of California, San Diego, U.S.A.
    • Department of Community and Family Medicine, 9500 Gilman Drive, La Jolla, CA 92093-0607, U.S.A.
    • ,
  • Michael H. Criqui

      Affiliations

    • Department of Community and Family Medicine, 0607 Division of Epidemiology, School of Medicine, University of California, San Diego, U.S.A.
    • Department of Community and Family Medicine, 9500 Gilman Drive, La Jolla, CA 92093-0607, U.S.A.
    • ,
  • Heather S. Feigelson

      Affiliations

    • Department of Community and Family Medicine, 0607 Division of Epidemiology, School of Medicine, University of California, San Diego, U.S.A.
    • Department of Community and Family Medicine, 9500 Gilman Drive, La Jolla, CA 92093-0607, U.S.A.
    • ,
  • Theresa J. McCann

      Affiliations

    • Department of Community and Family Medicine, 0607 Division of Epidemiology, School of Medicine, University of California, San Diego, U.S.A.
    • Department of Community and Family Medicine, 9500 Gilman Drive, La Jolla, CA 92093-0607, U.S.A.
    • ,
  • Robert N. Hamburger

      Affiliations

    • Department of Community and Family Medicine, 0607 Division of Epidemiology, School of Medicine, University of California, San Diego, U.S.A.
    • Department of Community and Family Medicine, 9500 Gilman Drive, La Jolla, CA 92093-0607, U.S.A.

,Revised 12 April 1995

References 

  1. Rosenman RH, Bland RJ, Jenkins CD, et al.  Coronary heart disease in the Western Collaborative Group Study. Final follow-up experience of 8 years. JAMA. 1975;233:872–877
  2. Knauer KA, Lichtenstein LM, Adkinson NF, et al.  Platelet activation during antigen-induced airway reactions in asthmatic subjects. N Engl J Med. 1981;304:1404–1407
  3. Joseph M, Thorel T, Tsicopoulos A, et al.  Nedocromil sodium inhibition of IgE-mediated activation of human mononuclear phagocytes and platelets from asthmatics. Drugs. 1989;37(1):32–36
  4. Tsicopoulos A, Tonnel AB, Wallaert B, et al.  A circulating suppressive factor of platelet cytotoxic functions after rush immunotherapy in hymenoptera venom hypersensitivity. J Immunol. 1989;142(8):2683–2688
  5. Gresele P, Todisco T, Merante F, et al.  Platelet activation and allergic asthma (letter). N Engl J Med. 1982;306:549
  6. Morley J, Sanjar S, Page CP. The platelet in asthma. Lancet. 1984;2:1142–1144
  7. Shimokawa H, Tomblike H, Nabeyama S, et al.  Coronary artery spasm induced in atherosclerotic miniature swine. Science. 1983;221:560–562
  8. Kalsner S, Richards R. Coronary arteries of cardiac patients are hyperactive and contain stores of amines: a mechanism for coronary spasm. Science. 1984;223:1435–1437
  9. Ginsburg R, Bristow MR, Davis K, et al.  Quantitative pharmacological responses of normal and atherosclerotic isolated human epicardial coronary arteries. Circulation. 1984;69:430–440
  10. Ginsburg R, Bristow MR, Kantrowitz N, et al.  Histamine provocation of clinical coronary artery spasm: implications concerning pathogenesis of variant angina pectoris. Am Heart J. 1981;102:819–822
  11. Forman MB, Oates JA, Robertson D, et al.  Increased adventitial mast cells in a patient with coronary spasm. N Engl J Med. 1985;313:1138–1141
  12. Criqui MH, Seibles J, Hamburger RN, et al.  Epidemiology of immunoglobulin E levels in a defined population. Ann Allergy. 1990;64:308–313
  13. Criqui MH, Lee ER, Hamburger RN, et al.  IgE and cardiovascular disease results from a population-based study. Am J Med. 1987;82:964–968
  14. Gerrard JW, Heiner DC, Ko CG, et al.  Immunoglobulin levels in smokers and nonsmokers. Ann Allergy. 1980;44:261–262
  15. Burrows B, Halonen M, Barbee RA, et al.  The relationship of serum immunoglobulin E to cigarette smoking. Am Rev Respir Dis. 1981;124:523–525
  16. Zetterstrom O, Osterman K, Machado L, et al.  Another smoking hazard: raised serum IgE concentration and increased risk of occupational allergy. Br Med J (Clin Res). 1981;283:1215–1217
  17. Burrows B, Halonen M, Lebowitz MD, et al.  The relationship of serum immunoglobulin E, allergy, skin tests, and smoking to respiratory disorders. J Allergy Clin Immunol. 1982;70:199–204
  18. Warren CP, Holford-Strevens V, Wong C, et al.  The relationship between smoking and total immunoglobulin E levels. J Allergy Clin Immunol. 1982;68:370–375
  19. Hallgren R, Nou E, Arrendale H, et al.  Smoking and circulating IgE in bronchial carcinoma. Acta Med Scand. 1982;211:269–273
  20. Bahna SC, Heiner DC, Myhre BA. Immunoglobulin E pattern in cigarette smokers. Allergy. 1983;38:57–64
  21. Taylor RG, Gross E, Joyce H, et al.  Smoking, allergy, and the differential white blood cell count. Thorax. 1985;40:17–22
  22. Venables KM, Topping MD, Howe W, et al.  Interaction of smoking and atopy in producing specific IgE antibody against a hapten protein conjugate. Br Med J. 1985;290:201–204
  23. Bloom JW, Halonen M, Dunn AM, et al.  Pneumococcus-specific immunoglobulin E in cigarette smokers. Clin Allergy. 1986;16:25–32
  24. Szczeklik A, Sladek K, Szczerba A, et al.  Serum immunoglobulin E response to myocardial infarction. Circulation. 1988;77:1245–1249
  25. Ceska M, Lundkvist U. A new and simple radioimmunoassay method for the determination of IgE. Immunochemistry. 1972;9:1021–1030
  26. Lipid Research Clinics Program. Manual of Laboratory Operations, vol.1. Lipid and Lipoprotein Analysis. In: 3rd Ed. DHEW publication no. (NIH) 75-628. Bethesda, MD: National Heart, Lung, and Blood Institute. National Institutes of Health; 1974;
  27. SPSS Inc. . SPSS/PC + for the IBM PC/XT/AT. Chicago, IL: Author; 1986;
  28. Epicenter Software . Epilog Plus—Statistics package for epidemiology and clinical trials. Pasadena, CA: Author; 1990;
  29. Maseri A. Coronary vasoconstriction: visible and invisible (editorial). N Engl J Med. 1991;325:1578–1579
  30. Kaartinen M, Penttila A, Kovanen PT. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation. 1994;90:1669–1678
  31. Barbash GI, White HD, Modan M, Diaz R, Hampton JR, Heikkila J, et al. Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: experience gleaned from the international tissue plasminogen activator/streptokinase mortality trial. Circulation. 1993;87:53–58
  32. McKenna WJ, Chew CYC, Oakley CM. Myocardial infarction with normal coronary angiogram: possible mechanism of smoking risk in coronary artery disease. Br Heart J. 1980;43:493–498
  33. Cryer PE, Haymond MW, Santiago JV, Shah SD. Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemo-dynamic and metabolic events. N Engl J Med. 1976;53:354–355
  34. Cryer PE, Maouad J, Fernandez F, Barrillon A, Gerbaux A, Gay J. Diffuse or segmental narrowing (spasm) of the coronary arteries during smoking demonstrated on angiography. Am J Cardiol. 1984;53:354–355
  35. Criqui MH. Serum immunoglobulin E after myocardial infarction (letter). Circulation. 1988;78:1322

☆ This work was supported by the University of California Tobacco Related Disease Research Program Award no. 1RT 468.

PII: 0895-4356(95)00548-X

Journal of Clinical Epidemiology
Volume 49, Issue 2 , Pages 203-209 , February 1996

Article Tools